Oscar Goodman, M.D., Ph.D.
Assistant Member, Department of Clinical Oncology
Dr. Goodman, a native of Las Vegas, received his B.A. from Swarthmore College in chemistry. In 1999 he received his M.D. from Jefferson Medical College and his Ph.D. from Thomas Jefferson University, both located in Philadelphia. He completed his internal medicine internship and residency, and hematology and medical oncology fellowship at New York Presbyterian Hospital- Cornell campus, where he also served as a chief fellow. He joined NVCI after formerly serving as an assistant attending physician at New York Presbyterian Hospital and an assistant professor in the Department of Medicine at Cornell University College of Medicine in New York.
Dr. Goodman is a physician-scientist and a member of the genitourinary oncology interdisciplinary team. He sees patients with prostate, bladder and testes cancers. He has been named as a Castle-Connolly regional Top Doctor. His basic research focuses on the role of cell-surface peptidases in the regulation of signaling events, both on malignant epithelial cells and vascular endothelial cells. By regulating local ligand concentrations, one such enzyme, neutral endopeptidase, or NEP (CD10, CALLA) regulates the initiation of cell surface signaling events. This enzyme functions as a tumor suppressor gene product in prostate cancer and also directly modulates other signal transduction pathways, such as the PI3-K/Akt pathway.
Its expression is androgen-dependent and thus alterations in its expression are believed to directly contributing to the development of castration-resistant prostate cancer. The overarching goal of Dr. Goodman’s research is to develop novel anticancer drugs that mimic or augment the activity, as well as to develop personalized therapeutic approaches for prostate cancer based on cell surface peptidase expression patterns.
In collaboration with other NVCI faculty, Dr. Goodman has assumed a lead role conducting clinical research on circulating tumor cells (CTC) in prostate cancer (these are cells of epithelial origin that can be isolated from the bloodstream of patients with cancer). Enumerating CTC has both prognostic and predictive value and can be detected in the majority of patients with advanced prostate cancer.
Dr. Goodman’s research into circulating tumor cells is to develop novel platforms utilizing these cells as biomaterial to develop personalized therapies for men with prostate cancer.
Recent Peer Reviewed Publications:
Chan F, Goodman O, Fink L, Vogelzang NJ, Pomerantz D, Khoury JD. Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate. Arch Pathol Lab Med. 2010 Jan;134(1):120-3.
Goodman, OB Jr., Fink, L.M., Symanowski, J.T., Wong, B., Grobaski, B., Pomerantz, D. Ma, Y., Ward D.C., and Vogelzang, N.J. Circulating tumor cells in patients with castration-resistant prostate cancer- baseline values and correlation with prognostic factors (2009) Cancer Epidemiol Biomarkers 18(6): 1904-1913
Goodman OB, Milowsky MI, Kaplan J, Hussain M, Nanus DM Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature. J. Med Case Reports. 2009 Sep 15;3:9110
Goodman OB Jr. and Dang, N.H. Novel Antibody Approaches for T-Cell Lymphomas (2008) Clinical Lymphoma & Myeloma; Vol. 8, Suppl. 5, S193-S198
Goodman, Jr. O.B., Barwe, S.P., Ritter, B., McPherson, P.S., Vasko, A-J, Keen, J.H., Nanus, D.M., Bander, N.H. and Rajasekaran, A.K. (2007) Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2, Int J Oncol. 31(5):1199-203
Goodman, Jr. O.B., Febbraio M., Simantov R., Zheng R., Shen R., Silverstein R.L., Nanus DM. (2006) Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem 281, 33597-605
